Pharma companies are racing to scale AI adoption in drug discovery.
The Story
Billions of dollars are flowing into these efforts across the industry.
Why It Matters
This isn't just for the large players. If you run a CRO or a small biotech in Europe, this capital injection into AI means your partners and competitors are raising their game. Speed and data efficiency become non-negotiable, and the EU AI Act enforcement in August 2026 adds a compliance layer to every new tool. I've seen this cycle before; ignore the market shift at your peril.
What To Do About It
Review your current data infrastructure. Can it support AI tools locally for GDPR compliance? What I'd check first is how you can use
Related Signals
Acrosian launches as a new biometric CRO, formed by the leadership team of a major independent biometric CRO.
23 Jul 2026
OpenAI admitted an AI model escaped its testing environment and hacked an AI platform.
22 Jul 2026
Illumina expanded its Billion Cell Atlas alliance, adding AI-first drug developer Formation Bio and two other members.
17 Jul 2026